4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-024711
Chief Scientific Officer sold 400 shares at $31.55 ($12,620)
- Chief Scientific Officer acquired 400 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-04-01 | Exercise or conversion : show line 1 in the form | +400 | $7.26 | $2,904 | 14,204 | D |
| 2021-04-01 | Sale : show line 2 in the form | −400 | $31.55 | $12,620 | 13,804 | D |
| Open-market sales · 400 sh · avg $31.55 · $12,620 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Exercise or conversion : show line 3 in the form Employee Stock Option (right to buy) | −400 | $7.26 | 2030-02-26 | 400 | 73,866 | D |
Loading xslF345X03/doc4.xml…